Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Aiforia investor webinar: Customer pipeline maturing gradually

AIFORIAAnalyst Comment18.11.2026, 08.28
Antti SiltanenAnalyst
Discuss

Summary

  • Preliminary results from Veneto’s pilot indicate that Aiforia cut pathologists’ working time and prostate-biopsy turnaround times by about 50%. The region will extend its contract by one year and plans to broaden AI use.
  • Aiforia has more than 20 clinical key accounts, with seven in production. Management says contracts typically take 6–9 months to generate revenue, while some deployments are delayed by customers’ own projects.
  • DeciBio estimates the market at 1.2 BUSD, with 12% annual growth to 2.1 BUSD by 2031. The analyst’s 4.6 MEUR revenue forecast for next year depends on account conversion.
  • Management says Aiforia has about 12 months of cash runway, including part of its EIB loan. If conditions prevent later tranches, additional financing may be needed as early as next year.

This content is generated by AI. You can give feedback on it in the Inderes forum.

Translation: Original published in Finnish on 11/18/2026 at 7:45 am EET.

Aiforia held an investor webinar on Tuesday, a recording of which is available here. In addition to CEO Jukka Tapaninen, the speakers included Angelo Paolo Dei Tos, Professor of Pathology at the University of Padua, and Katie Gillette Maloney, a Partner at the consulting firm DeciBio who specializes in digital pathology. The event provided interesting additional insight into the state of the customer base, hospital customers’ user experiences, and how far the market has developed.

Concrete research evidence from Veneto on the solutions’ usefulness

Dei Tos said that the Veneto region, with a population of ~5 million, selected Aiforia through a competitive tender as the region’s shared digital pathology AI platform. The region processes ~3 million glass slides a year. The payer asked the region for a pilot study, and data has been collected for ~2 months. According to preliminary results, both pathologists’ working time and turnaround times for prostate biopsies have fallen by ~50%. The current contract formally ends at the turn of the year, but it will be extended by one year. The region is already preparing a new procurement for broader use of AI, and next year, the plan is to extend use to areas including HER2 analysis in breast cancer. As we understand it, the new procurement is open to competition, but we believe Aiforia’s position in it is very strong.

Market growing, clinical use just beginning

According to DeciBio’s Maloney, the global digital pathology market is ~1.2 BUSD this year, of which AI solutions still account for only a fairly small share. The market is estimated to grow by ~12% a year to 2.1 BUSD by 2031. About two-thirds of spending comes from pharmaceutical and CRO companies, while the clinical side accounts for roughly one-third. Roughly 30% of pathology laboratories in the US and the five largest EU countries have a scanner, but only ~10% diagnose digitally. AI or image analysis tools are used by ~25% of laboratories in Europe and ~5% in the US. The US reimbursement system is still incomplete, and DeciBio estimates that broader payment models will take another 3–5 years.

The figures support our view of the market’s long-term potential. Clinical growth in the coming years will rely on Europe and public payer initiatives. This fits Aiforia’s position well, as the company’s competitive advantage rests on a broad portfolio of CE-IVD-marked models. According to Maloney, end-to-end solutions from players such as Roche and Agilent make adoption easier for laboratories. In her view, these platforms could also expand the customer base of independent algorithm providers in the coming years.

Around one-third of key accounts in production use

For investors, the most important new information concerned the build-up of the customer base. Based on the webinar, Aiforia has over 20 clinical key accounts, seven of which are in production use. The solution has been delivered to some customers, but they have not yet started using it. Some customer accounts are still in the delivery phase. According to management, it typically takes 6–9 months for a contract to translate into revenue. Some contracts signed two years ago, however, are still not in use. This is due to the customers’ own scanner, laboratory information system, and image management projects. According to the company, active customers’ usage volumes have more than doubled since the start of the year.

The figures provide some visibility into the future, as delivered customer accounts and those in the delivery phase are the source of growth for the coming years. Based on the typical lag, contracts signed earlier in the year, such as those with AP-HP and in Spain, should start to show in revenue around the turn of the year. Our forecast for next year (revenue of 4.6 MEUR, +75%) requires a significant share of these customer accounts to move into production use.

Funding sufficient for about a year

According to Tapaninen, the company has a cash runway of ~12 months, which includes its current cash and part of the EIB loan. The 20 MEUR EIB loan is divided into three tranches (5, 7, and 8 MEUR). Drawing down the tranches requires meeting conditions tied to revenue and other milestones. Whether the funding is sufficient therefore depends on growth, as does the entire investment story. If later loan tranches cannot be drawn, additional financing may be needed as early as next year. The decisive factor remains how quickly signed contracts turn into revenue.

 

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more on company page

Key Estimate Figures04.11

202526e27e
Revenue3.52.74.6
growth-%24.0 %-25.0 %75.0 %
EBIT (adj.)-11.2-13.2-10.4
EBIT-% (adj.)-316.3 %-497.3 %-224.9 %
EPS (adj.)-0.38-0.36-0.30
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.neg.

Forum discussions

True as well, but there are certain universal valuation principles. Generally, weak growth and heavy losses are not a good combination for a...
7 hours ago
by Jorge B
6
Matter of taste, but in my view, determining a company’s valuation isn’t quite that straightforward at the startup/VC end, when guessing future...
9 hours ago
7
The share price has taken a well-deserved 2/3 drop from a year ago, but does the valuation make any sense even now? Growth is nowhere to be ...
10 hours ago
by Jorge B
3
In my own vision, talks are probably being held, considering the share price has been stuck in a deep rut and insiders haven’t made any share...
11 hours ago
by Salvelinus
6
Yes, I’ve often noticed this in Jukka’s comments as well. Maybe it’s already been discussed over coffee; the AI-phoria (Aiforia) just needs ...
12 hours ago
by Uuno
2
This talk of industry consolidation has been noteworthy. Previously, whenever Antti has interviewed Tapaninen, he has proactively brought this...
12 hours ago
3
I personally noticed how industry consolidation was brought up repeatedly; the CEO almost seemed to imply between the lines that “we are for...
12 hours ago
by Puutaheinää
11